Item 5.07 Submission of Matters to a Vote of Security Holders.

On January 15, 2025, Virpax Pharmaceuticals, Inc. (the "Company") held a special meeting (the "Special Meeting"). As of November 20, 2024, the record date for the 2025 Special Meeting, 8,087,581 shares of common stock, par value $0.00001 per share ("Common Stock"), were issued and outstanding. Holders of 5,253,501 shares of the Company's Common Stock were present in person or by proxy at the 2025 Special Meeting, representing approximately 64.96% of the total outstanding shares of Common Stock, constituting a quorum pursuant to the Company's bylaws. A summary of the matters voted upon by stockholders at the 2025 Special Meeting and the final voting results for each proposal, as described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on December 9, 2024, is set forth below:

Proposal No. 1 - The stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split with respect to the Company's Common Stock, at a ratio of 1-for-2 to 1-for-240 (the "Range"), with the ratio within such Range to be determined at the discretion of the Board in its sole discretion. The results of the voting for this approved proposal were as follows:

For

Against

Abstain

Broker Non-Votes

4,069,610

1,117,444

66,447

Not applicable

Proposal No. 2 - The Company's stockholders elected five (5) directors to serve until the 2025 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified. The elected directors are Jatinder Dhaliwal, Katharyn Field, Jaydriane Panis, Judy Su, and Esha Randhawa. The results of the voting for this approved proposal were as follows:

Matter Being Voted On		For		Against		Abstain		Broker Non- Votes
Jatinder Dhaliwal			3,002,603				442,036				13,008				1,795,854
Katharyn Field			3,003,366				441,276				13,005				1,795,854
Jaydriane Panis			2,984,071				441,423				32,153				1,795,854
Judy Su			3,005,187				439,452				13,008				1,795,854
Esha Randhawa			3,003,187				441,452				13,008				1,795,854

Proposal No. 3 - The stockholders did not approve the adjournment of the 2025 Special Meeting to a later date or date, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposal Number 1 and/or Proposal Number 2, based on the votes set forth below. The results of the voting for this approved proposal were as follows:

For

Against

Abstain

Broker Non-Votes

4,419,257

768,408

65,836

Not applicable

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Public link

Please use the above public link if you want to share this noodl on another website.